NatAb™: An unprecedented platform for antibody discovery

NatAb™ is a novel and simple-to-implement platform for native antibodies identification and characterization. The development of high-throughput sequencing of immune repertoire has broadened the understanding adaptive responses for antibody discovery and in clinical practice. However, the variable domains of antibody heavy and light chains (VH and VL, respectively) are encoded by different mRNA transcripts. The determination of native antibody variable heavy-light pairs (VH-VL pairs) remains a major challenge, which will limit the development of novel antibodies as well as therapeutic drugs. Our platform overcomes the main obstacles in the conventional technologies and enables the rapid identification of drug candidates.

Rapid Identification of the lead antibody

By incorporating a fluidic droplet based ultra-high throughput B cell sorting technology, millions of antibody secreting B cells could be screened based on the affinity to an antigen or other functions in hours.

An in-depth comprehension of antibody repertoire

We amplify the paired VH-VL sequence with a barcode. Via NatSeq™ platform, natively paired immune receptor repertoire could be determined at great depth. It provides valuable insights on autoimmunity, infectious diseases and many other medically and immunologically important issues.

Faster speed, better result, higher performance.

- Various targets from soluble protein to cell-surface targets and even bacteria.
- Different antibody sources from all animal species including human.
- Extraordinary deep-mining of paired antibody repertoire.

Please note: our NatAb™ platform can only provide services for research purposes. No clinical or therapeutic applications, please.